Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anna Coleman

Showing results (41-50 of 56) with videos related to

Pageof 6
Sort By:
BMJ Open|April 17, 2019
Exploring the impacts of the 2012 Health and Social Care Act reforms to commissioning on clinical activity in the English NHS: a mixed methods study of cervical screeningJonathan Hammond, Thomas Mason, Matt Sutton, et al.
Pediatric Dermatology|February 3, 2024
A case series of live attenuated vaccine administration in dupilumab-treated children with atopic dermatitisElaine C Siegfried, Lara Wine Lee, Jonathan M Spergel, et al.
Biology Letters|August 29, 2014
Persistent social interactions beget more pronounced personalities in a desert-dwelling social spiderAndreas P Modlmeier, Kate L Laskowski, Alex E DeMarco, et al.
BMC Public Health|June 21, 2023
Areas of enduring COVID-19 prevalence: drivers of prevalence and mitigating strategiesCatherine Lewis, Sheena Johnson, Angelique Hartwig, et al.
Advances in Therapy|May 19, 2026
Summary of Research: Dupilumab Safety for Treating Infants to Adults with Moderate-to-Severe Atopic DermatitisRichard G Langley, Guy Gherardi, Anna Coleman, et al.
American Journal of Clinical Dermatology|September 24, 2025
The Safety Data of Dupilumab for the Treatment of Moderate‑to‑Severe Atopic Dermatitis in Infants, Children, Adolescents, and AdultsRichard G Langley, Guy Gherardi, Anna Coleman, et al.
JAMA Dermatology|July 10, 2024
Dupilumab in Adults With Moderate to Severe Atopic Dermatitis: A 5-Year Open-Label Extension StudyLisa A Beck, Robert Bissonnette, Mette Deleuran, et al.
Advances in Therapy|January 21, 2026
Dupilumab Treatment Up to 5 Years Shows No Clinically Meaningful Changes in Laboratory Parameters in Adults with Moderate-to-Severe Atopic DermatitisEric L Simpson, Robert Bissonnette, Mette Deleuran, et al.
Pediatric Dermatology|November 12, 2024
Low Infection Rates With Long-Term Dupilumab Treatment in Patients Aged 6 Months to 5 Years: An Open-Label Extension StudyAmy S Paller, Michele Ramien, Michael J Cork, et al.
Dermatitis : Contact, Atopic, Occupational, Drug|October 30, 2025
Facial Rash Events in Dupilumab Phase 3 Atopic Dermatitis Trials: A Pooled AnalysisAmy S Paller, Marjolein de Bruin-Weller, Eric L Simpson, et al.
Pageof 6

Showing results (41-50 of 56) with videos related to

Sort By:
Pageof 6
BMJ Open|April 17, 2019
Exploring the impacts of the 2012 Health and Social Care Act reforms to commissioning on clinical activity in the English NHS: a mixed methods study of cervical screeningJonathan Hammond, Thomas Mason, Matt Sutton, et al.
Pediatric Dermatology|February 3, 2024
A case series of live attenuated vaccine administration in dupilumab-treated children with atopic dermatitisElaine C Siegfried, Lara Wine Lee, Jonathan M Spergel, et al.
Biology Letters|August 29, 2014
Persistent social interactions beget more pronounced personalities in a desert-dwelling social spiderAndreas P Modlmeier, Kate L Laskowski, Alex E DeMarco, et al.
BMC Public Health|June 21, 2023
Areas of enduring COVID-19 prevalence: drivers of prevalence and mitigating strategiesCatherine Lewis, Sheena Johnson, Angelique Hartwig, et al.
Advances in Therapy|May 19, 2026
Summary of Research: Dupilumab Safety for Treating Infants to Adults with Moderate-to-Severe Atopic DermatitisRichard G Langley, Guy Gherardi, Anna Coleman, et al.
American Journal of Clinical Dermatology|September 24, 2025
The Safety Data of Dupilumab for the Treatment of Moderate‑to‑Severe Atopic Dermatitis in Infants, Children, Adolescents, and AdultsRichard G Langley, Guy Gherardi, Anna Coleman, et al.
JAMA Dermatology|July 10, 2024
Dupilumab in Adults With Moderate to Severe Atopic Dermatitis: A 5-Year Open-Label Extension StudyLisa A Beck, Robert Bissonnette, Mette Deleuran, et al.
Advances in Therapy|January 21, 2026
Dupilumab Treatment Up to 5 Years Shows No Clinically Meaningful Changes in Laboratory Parameters in Adults with Moderate-to-Severe Atopic DermatitisEric L Simpson, Robert Bissonnette, Mette Deleuran, et al.
Pediatric Dermatology|November 12, 2024
Low Infection Rates With Long-Term Dupilumab Treatment in Patients Aged 6 Months to 5 Years: An Open-Label Extension StudyAmy S Paller, Michele Ramien, Michael J Cork, et al.
Dermatitis : Contact, Atopic, Occupational, Drug|October 30, 2025
Facial Rash Events in Dupilumab Phase 3 Atopic Dermatitis Trials: A Pooled AnalysisAmy S Paller, Marjolein de Bruin-Weller, Eric L Simpson, et al.
Pageof 6